YOLFTbeta
30

Wuhan Hiteck Biological Pharma Co Ltd

300683 · SHE · Healthcare / Drug Manufacturers - Specialty & Generic

23.30CNY+0.77 (+3.42%)

Price History

Full chart

Market Stats

Previous Close22.53
Open22.70
Day Range22.21 – 24.32
52-Week Range22.37 – 50.68
Volume9.92M
Market Cap3.34B
P/E (TTM)0.00
Forward P/E0.00
EPS-2.07
Dividend Yield0.00%
Beta-0.33
50-Day Avg26.33
200-Day Avg30.23

About

Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the production and sales of bioengineering products and lyophilized powder injections in China and internationally. The company operates through Biopharmaceutical Division; Pharmaceutical Technology Services Division; In Vitro Diagnostic Reagents Division; Production and Sales Division of Active Pharmaceutical Ingredients and Pharmaceutical Intermediates; and Other Divisions segments. Its products include Epramine for injection; mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis; tinidazole suppository, acyclovir dispersible tablets, nimodipine extended-release tablets, trimetazidine hydrochloride tablets, azithromycin granules, esomeprazole sodium for injection, and cyclic adenosine monophosphate for injection; Pentoxone theobromine injection; Roxatidine Acetate Hydrochloride for Injection; and Terizazole phosphate for injection. The company also provides measles and rubella virus nucleic acid detection kits; isolation and identification tubes and kits for mycoplasma; and bacterial vaginosis (BV) rapid test kits, as well as diagnostic kits for novel coronavirus N-Protein, as well as raw materials and intermediates. In addition, it offers diagnostic kits for IgG antibody to measles virus, hydatid, toxoplasma, rubella virus, cytomegalo virus, and herpes simplex virus I/II; diagnostic kits for IgM antibody to measles virus, herpes simplex virus I/II, cytomegalo virus, rubella virus, and toxoplasma; and diagnostic kits for a "Thalassemia. Further, the company provides Lopinavir and Ritonavir APIs, and intermediates. It offers its products in the field of nervous system and oncology. Wuhan Hiteck Biological Pharma Co.,Ltd was founded in 1992 and is based in Wuhan, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMs. Wen Xian
  • Employees958
  • HeadquartersHaite Science and Technology Park, Wuhan, China, 430056, China
  • Websitehttps://www.hiteck.com.cn

Leadership

  • Ms. Wen XianFinancial Director, Accounting Supervisor & Non-Independent Director · b. 1975
  • Mr. Huang ChenDeputy GM & Director · b. 1975
  • Mr. Kun YangSecretary of Board of Directors · b. 1987

Financials

Income Statement

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue355.99M548.79M679.41M770.97M750.26M590.87M620.16M524.12M614.68M688.63M602.28M648.97M541.45M
Growth (%)-+54.16%+23.80%+13.48%-2.69%-21.24%+4.96%-15.49%+17.28%+12.03%-12.54%+7.75%-16.57%
Cost of Revenue18.75M27.11M68.00M35.59M35.16M44.48M120.26M215.42M264.86M358.87M369.73M380.88M310.57M
Gross Profit337.24M521.68M611.41M735.38M715.10M546.39M499.90M308.70M349.82M329.75M232.56M268.09M230.88M
Gross Margin94.73%95.06%89.99%95.38%95.31%92.47%80.61%58.90%56.91%47.89%38.61%41.31%42.64%
Operating Expense247.42M393.01M516.87M553.50M558.65M441.14M424.85M343.78M328.48M336.57M375.63M343.80M352.65M
Operating Income89.83M128.68M94.54M181.88M156.45M105.25M75.05M-35.08M21.34M-6.82M-143.07M-75.71M-121.77M
Operating Margin25.23%23.45%13.91%23.59%20.85%17.81%12.10%-6.69%3.47%-0.99%-23.76%-11.67%-22.49%
EBITDA91.87M134.55M104.00M198.76M183.03M118.95M95.82M-7.91M56.57M44.48M-80.91M9.74M-140.03M
EBITDA Margin25.81%24.52%15.31%25.78%24.40%20.13%15.45%-1.51%9.20%6.46%-13.43%1.50%-25.86%
Net Income77.65M109.91M83.35M157.05M142.39M94.14M63.04M-25.03M27.65M-14.03M-120.82M-69.35M-231.27M
Net Income Margin21.81%20.03%12.27%20.37%18.98%15.93%10.16%-4.77%4.50%-2.04%-20.06%-10.69%-42.71%
R&D10.66M16.96M25.11M30.03M24.50M29.86M62.65M86.12M103.17M121.43M128.90M121.75M88.24M
R&D as % of Total Revenue2.99%3.09%3.70%3.90%3.27%5.05%10.10%16.43%16.78%17.63%21.40%18.76%16.30%
Interest Expense-41.80K205.13K129.40K8.19M433.15K245.55K1.03M1.06M1.61M2.86M3.01M1.39M
Interest Expense % of Total Revenue-0.01%0.03%0.02%1.09%0.07%0.04%0.20%0.17%0.23%0.47%0.46%0.26%

Balance Sheet

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets441.07M801.37M872.49M1.04B1.91B2.16B2.17B2.19B2.70B2.71B2.97B2.94B2.58B
Total Liabilities186.42M264.78M275.74M335.87M265.62M445.77M409.03M461.62M354.46M371.20M475.73M525.05M407.14M
Total Equity253.10M534.56M596.04M696.82M1.64B1.70B1.75B1.71B2.32B2.31B2.48B2.39B2.16B
Cash174.91M472.23M496.45M607.98M697.58M307.07M695.59M460.82M184.05M748.48M510.22M419.15M648.33M
Total Debt---2.45M2.45M2.45M2.45M6.49M111.03M102.65M44.04M24.10M-
Net Debt-174.91M-472.23M-496.45M-605.53M-695.13M-304.62M-693.14M-454.34M-73.02M-645.83M-444.26M-395.05M-

Cash Flow

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow76.82M135.40M159.89M143.86M83.08M73.42M63.03M-19.70M12.09M53.03M5.31M22.69M-76.54M
Investing Cash Flow-15.17M-11.77M-114.63M20.54M-792.95M-438.74M342.96M-196.14M-953.01M525.36M-491.93M-100.35M-
Financing Cash Flow-19.44M173.68M-21.04M-52.87M799.48M-25.20M-28.49M-8.18M662.82M-12.29M248.29M-13.43M-
Capital Expenditure15.71M15.64M13.62M22.05M22.25M38.67M116.15M113.63M247.11M173.97M167.44M43.08M50.54M
Free Cash Flow61.11M119.76M146.26M121.81M60.82M34.75M-53.13M-133.33M-235.02M-120.94M-162.13M-20.39M-127.07M
Dividends Paid1.04M-46.34M60.87M31.01M31.17M20.67M16.54M62.00K1.34M2.20M1.76M17.87M
FCF to OCF79.54%88.45%91.48%84.67%73.21%47.33%-84.29%676.71%-1944.24%-228.04%-3050.79%-89.90%166.03%
Dividend Paid to FCF1.70%-31.68%49.97%50.98%89.67%-38.91%-12.40%-0.03%-1.11%-1.36%-8.64%-14.06%

Earnings

Report DateOct 25, 2017Dec 31, 2017Apr 26, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Apr 28, 2020Aug 29, 2020Oct 27, 2020Dec 31, 2020Apr 23, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023May 16, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024May 16, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------------------------
EPS Actual0.380.330.230.220.290.180.290.250.12-0.050.04-0.08-0.07-0.140.14-0.070.110.070.060.09-0.00-0.27-0.01-0.07-0.12-0.72-0.13-0.05-0.13-0.23-0.11-0.19-0.91-0.56-0.18-0.43
Surprise------------------------------------
TimingAfter-hours-Pre-market-----------------------After-hours---After-hours-----

Key Statistics & Ratios

Market Cap3.34B
Enterprise Value3.07B
Trailing P/E0.00
Forward P/E0.00
Price / Sales6.80
Price / Book1.64
EPS-2.07
Book Value15.91
Revenue (TTM)491.90M
Gross Profit (TTM)182.32M
EBITDA-92.13M
Profit Margin-55.05%
Operating Margin-107.67%
Return on Equity-12.36%
Return on Assets-4.43%
Shares Outstanding130.89M
Shares Float72.36M
Beta-0.33
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20251×
0.13Jan 9, 2025
20201×
0.16Jul 1, 2020
20191×
0.20Jun 17, 2019
20181×
0.30May 23, 2018